RELAPSED NON-HODGKIN LYMPHOMA

Clinical trials for RELAPSED NON-HODGKIN LYMPHOMA explained in plain language.

Never miss a new study

Get alerted when new RELAPSED NON-HODGKIN LYMPHOMA trials appear

Sign up with your email to follow new studies for RELAPSED NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 10 Not yet recruiting 1 Not yet finished but already full! 5 Completed 4

New hope for Hard-to-Treat lymphoma: drug cocktail enters human trials

Disease control Not yet recruiting

This study tests a combination of four drugs (homoharringtonine, a BCL-2 inhibitor, rituximab, and prednisone) in 62 adults with relapsed or refractory diffuse large B-cell lymphoma. The goal is to find the safest dose and see if the combo can shrink tumors. It's an early-phase t…

Matched conditions: RELAPSED NON-HODGKIN LYMPHOMA

Phase: PHASE1, PHASE2 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control

Last updated Jun 26, 2026 14:55 UTC

RELAPSED NON-HODGKIN LYMPHOMA

Get alerted when new RELAPSED NON-HODGKIN LYMPHOMA trials appear

New hope for Hard-to-Treat lymphoma: drug cocktail enters human trials